Organigram (TSX.V:OGI, OTCQB:OGRMF) began a voluntary recall of a total of 74 products produced between February 1 and December 16, 2016. These lots tested positive for two pesticides that aren't authorized for use on cannabis plants under the Pest Control Products Act but there are long-term benefits for the recall.
AusCann recently went public via a reverse takeover on the ASX. Their joint-venture with Daya Foundation in Chile and Canopy Growth in Canada puts them at the head of the pack in the Australian market. Canopy Growth Corporation will potentially make the move to buy AusCann.
When heated, myclobutanil is known to create hydrogen cyanide which is extremely poisonous. 3 of the 38 federally licensed marijuana growing companies have had to recall their products due to the presence of the myclobutanil pesticide.
Courtagen Life Sciences, Inc., has launched Avantra Genetics. Avantra is dedicated to providing advanced genomic information for functional medicine practices. Patients suffering from functional disorders may experience symptoms such as pain, fatigue, numbness or sensations and gastrointestinal distress that can be severe, chronic or debilitating.
Colorado is on the brink of becoming the first state with licensed pot clubs. But the details of how these clubs will operate are as hazy as the underground clubs operating already.
Shareholders of Medical Marijuana Inc. ($MJNA , a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year. So why is this company such a high risk for new Investors?
Aurora Cannabis Inc. (TSXV:ACB) is a high-flying Canadian medical marijuana producer that is slowly creeping up on Canopy Growth Corp. (TSX:WEED) and Aphria Inc. (TSXV:APH). The company has a $787 million market cap, but it could soon break the $1 billion mark later this year.
It's a race to riches that has just begun among a handful of Canada’s licensed, industrial-scale medical marijuana growers – each of whom wants to capitalize on in-house IP that can turn cannabis into mainstream medicine. In the quest to find the next GW, Dundee Capital Markets is championing Emerald Heath Therapeutics Inc.
While the medicinal cannabis industry continues to rapidly advance and expand operations by identifying new leading edge products, leaders are turning towards the expertise and knowledge of other medical sectors, especially with influence from the biopharma sector.
Valens GroWorks Corp. (CSE: VGW) together with its subsidiary is pleased to announce its engagement under a 5-year, renewable, Professional Services Agreement with Arizona-based marijuana cultivation and medicinal dispensary business MKHS.
InMed Pharmaceuticals Inc. (CSE:IN, OTCQB:IMLFF) is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs.
Tetra Bio-Pharma (CSE: TBP) (CSE: TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that Health Canada has approved its Phase I clinical study of smoked cannabis.
In Canada, medical marijuana patients have the option to get their medication in dried form, as a concentrated oil or even fresh. Right now there are 38 approved licensed producers of medical marijuana of which only 22 produce oil. So why should this matter to Investors?
Spirit Gold (SG.v) once an exploration stage company engaged in acquiring, exploring and evaluating mineral resource has turned their attention to Marijuana. Spirit Gold Entered Into Definitive Agreement to Acquire Northern Lights Marijuana Company.
Tetra Bio-Pharma Inc. (CSE: TBP, OTC:GRPOF) and IntelGenx Corp. (TSXV:IGX, OTCQX:IGXT), annouced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.
